| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
91,542 |
47,362 |
$5.35M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
12,292 |
4,130 |
$933K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
41,200 |
19,841 |
$438K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
6,730 |
6,162 |
$345K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,027 |
1,007 |
$248K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
2,960 |
2,865 |
$144K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
7,904 |
3,304 |
$128K |
| 88312 |
|
2,689 |
2,556 |
$90K |
| 88313 |
|
2,357 |
2,233 |
$74K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,636 |
927 |
$63K |
| 87481 |
|
1,295 |
1,243 |
$49K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
1,342 |
1,339 |
$34K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,224 |
1,210 |
$31K |
| 87486 |
|
1,087 |
1,062 |
$27K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,220 |
1,206 |
$25K |
| 87581 |
|
1,088 |
1,063 |
$25K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,234 |
1,228 |
$23K |
| 87511 |
|
1,048 |
1,036 |
$22K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
490 |
455 |
$21K |
| 88112 |
|
904 |
861 |
$21K |
| 88344 |
|
281 |
227 |
$20K |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
302 |
302 |
$19K |
| 88342 |
|
639 |
613 |
$17K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
145 |
139 |
$17K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,315 |
1,274 |
$10K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
141 |
134 |
$7K |
| 88341 |
|
148 |
140 |
$4K |
| G0416 |
Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method |
42 |
42 |
$3K |
| 87500 |
|
202 |
183 |
$3K |
| 87640 |
|
239 |
221 |
$3K |
| 87641 |
|
203 |
186 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
54 |
54 |
$2K |
| 87653 |
|
139 |
124 |
$1K |
| 87563 |
|
67 |
65 |
$872.36 |
| 87529 |
|
35 |
33 |
$724.34 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
22 |
21 |
$216.78 |
| 88304 |
|
14 |
13 |
$163.32 |